Sharwan Hudda
Overview
Explore the profile of Sharwan Hudda including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
9
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vijay N, Taleuzzaman M, Hudda S, Choudhary N
Chem Biodivers
. 2024 Oct;
22(3):e202401969.
PMID: 39434408
The aim of study is to investigate the various mechanism-based antioxidant and anti-fungal properties of a hydroalcoholic extract of Ocimum basilicum L leaves. Additionally, conduct molecular docking to simultaneously validate...
2.
Khan S, Ahmad M, Ullah Z, Hashmi S, Ali M, Hudda S
Curr Comput Aided Drug Des
. 2024 Mar;
PMID: 38486382
Background: The purpose of this research is to develop an analytical method and validate it according to ICH guidelines for the estimation of Toremifene by RP-HPLC-PDA with molecular docking and...
3.
Chaudhary M, Shaik S, Magan M, Hudda S, Gupta M, Singh G, et al.
Curr Org Synth
. 2024 Feb;
PMID: 38310554
The [4+2] Diels-Alder cycloaddition has been widely used for the synthesis of six-mem-ber scaffolds. In recent years, there have been significant developments in this area, including the discovery and design...
4.
Somwanshi A, Wadhwa P, Raza A, Hudda S, Magan M, Khera K
Curr Pharm Des
. 2023 Oct;
29(29):2281-2290.
PMID: 37818585
Background: Due to potential toxicity, non-biodegradable polymers used in 3D (3-dimensional) printing of drugs could be dangerous for patient safety and the environment. Objective: This review aims to investigate the...
5.
Venugopal S, Kaur B, Verma A, Wadhwa P, Magan M, Hudda S, et al.
Chem Biol Drug Des
. 2023 Apr;
102(2):357-376.
PMID: 37009821
Cancer is the second leading cause of death globally, with 9.6 million deaths yearly. As a life-threatening disease, it necessitates the emergence of new therapies. Resistance to current chemotherapies drives...